Limits...
Bortezomib-based treatment for multiple myeloma patients with renal impairment

View Article: PubMed Central - PubMed

ABSTRACT

Background:: Renal insufficiency is a common and severe complication of patients with multiple myeloma. The aim of this study was to evaluate bortezomib-based treatment for multiple myeloma patients with renal insufficiency.

Methods:: The Cochrane Library, Embase, PubMed, ISI, China National Knowledge Infrastructure, Chinese Biomedical Literature Service System, Chongqing VIP Database, and Wan Fang Data were systematically searched to identify observational studies from January 1, 2001, to December 31, 2015. Myeloma response rate and renal remission rate were pooled by using risk ratio and 95% confidence interval (CI). The Cochran Q and I statistics were used to assess heterogeneity. Sensitivity analysis was performed to test the feasibility of pooled results. Publication bias was conducted when included studies were ≥9. Furthermore, grades of evidence were performed to evaluate study quality.

Results:: Eleven retrospective cohort studies were included in the final analysis. The number of available studies and risk ratios (95% CI) were, respectively, 10 and 1.48 (95% CI: 1.28–1.71) for myeloma overall response, 6 and 3.69 (95% CI: 2.22–6.13) for myeloma complete response, 9 and 1.47 (95% CI: 1.28–1.69) for renal overall remission, and 8 and 1.49 (95% CI: 1.26–1.75) for renal complete remission. No significant publication bias was observed and sensitivity analysis confirmed the stability of results. The overall qualities of evidence were high for myeloma complete response and medium for the other 3 outcomes based on the Grading of Recommendations, Assessment, Development and Evaluation system.

Conclusion:: Current evidence indicated that bortezomib-based treatment could improve myeloma overall response (especially myeloma complete response) and renal overall remission (including renal complete remission).

No MeSH data available.


Related in: MedlinePlus

Funnel plot of included studies concerning (A) myeloma overall response and (B) renal overall remission. RR = risk ratio, SE = standard error.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5120900&req=5

Figure 4: Funnel plot of included studies concerning (A) myeloma overall response and (B) renal overall remission. RR = risk ratio, SE = standard error.

Mentions: A funnel plot analysis was carried out to detect the publication bias when selected studies were ≥9. The results showed that no significant publication bias was observed (Fig. 4A and B). Sensitivity analysis confirmed the stability of the results. There was no significant change observed concerning the primary outcomes after removing any included study, alternative effect measures (RR vs OR), as well as consideration on heterogeneity (random effects vs fixed effects) (results were omitted).


Bortezomib-based treatment for multiple myeloma patients with renal impairment
Funnel plot of included studies concerning (A) myeloma overall response and (B) renal overall remission. RR = risk ratio, SE = standard error.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5120900&req=5

Figure 4: Funnel plot of included studies concerning (A) myeloma overall response and (B) renal overall remission. RR = risk ratio, SE = standard error.
Mentions: A funnel plot analysis was carried out to detect the publication bias when selected studies were ≥9. The results showed that no significant publication bias was observed (Fig. 4A and B). Sensitivity analysis confirmed the stability of the results. There was no significant change observed concerning the primary outcomes after removing any included study, alternative effect measures (RR vs OR), as well as consideration on heterogeneity (random effects vs fixed effects) (results were omitted).

View Article: PubMed Central - PubMed

ABSTRACT

Background:: Renal insufficiency is a common and severe complication of patients with multiple myeloma. The aim of this study was to evaluate bortezomib-based treatment for multiple myeloma patients with renal insufficiency.

Methods:: The Cochrane Library, Embase, PubMed, ISI, China National Knowledge Infrastructure, Chinese Biomedical Literature Service System, Chongqing VIP Database, and Wan Fang Data were systematically searched to identify observational studies from January 1, 2001, to December 31, 2015. Myeloma response rate and renal remission rate were pooled by using risk ratio and 95% confidence interval (CI). The Cochran Q and I statistics were used to assess heterogeneity. Sensitivity analysis was performed to test the feasibility of pooled results. Publication bias was conducted when included studies were ≥9. Furthermore, grades of evidence were performed to evaluate study quality.

Results:: Eleven retrospective cohort studies were included in the final analysis. The number of available studies and risk ratios (95% CI) were, respectively, 10 and 1.48 (95% CI: 1.28–1.71) for myeloma overall response, 6 and 3.69 (95% CI: 2.22–6.13) for myeloma complete response, 9 and 1.47 (95% CI: 1.28–1.69) for renal overall remission, and 8 and 1.49 (95% CI: 1.26–1.75) for renal complete remission. No significant publication bias was observed and sensitivity analysis confirmed the stability of results. The overall qualities of evidence were high for myeloma complete response and medium for the other 3 outcomes based on the Grading of Recommendations, Assessment, Development and Evaluation system.

Conclusion:: Current evidence indicated that bortezomib-based treatment could improve myeloma overall response (especially myeloma complete response) and renal overall remission (including renal complete remission).

No MeSH data available.


Related in: MedlinePlus